Transpek Industry earnings calls.

Transpek Industry reported a challenging Q1 FY27 with revenue of Rs 155.1 croreCurrent reported value: Rs 155.1 crore. No comparable prior figure is available in the source record. (down 6.5% YoY) and EBITDA of Rs 24.1 croreCurrent reported value: Rs 24.1 crore. No comparable prior figure is available in the source record. (down 32.4% YoY) amid pricing pressures from Indian and global competitors and subdued demand in export markets. The company cited geopolitical tensions, elevated energy prices, and continued supply chain disruptions as headwinds. EBITDA margin contracted to 15.6% versus the year-ago period. Management provided 15-20% revenue growth guidanceCurrent reported value: 15-20% revenue growth guidance. No comparable prior figure is available in the source record. for FY27, driven by new acid chloride products (revenue expected to grow from Rs 4 crore to Rs 15 crore for one product alone) and upcoming polymer/additive commercialization. The Odisha greenfield expansion (~Rs 250 crore over 5-6 years) with 4-5 year payback is under active evaluation. Dupont's Aramid business contract transferred to Arline, with renewal discussions slated for Q4 CY26-Q1 CY27. The near-zero debt balance sheet provides flexibility for capex deployment. Key risk: potential non-renewal of the Arline contract and inability to monetize the Rs 300 crore Sylox investment due to illiquidity and shareholder agreement constraints.